[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367055-105":59,"doc-detail-367055-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","harnessing-il-27-challenges-and-potential-in-cancer-immunotherapy","Harnessing IL-27: challenges and potential in cancer immunotherapy","","IL-27 is a structurally immune-enhancing, pleiotropic two-chain cytokine belonging to the IL-12 and IL-6 cytokine families, composed of IL-27p28 and EBI3. Its heterodimer receptor, IL27Rα (WSX1) and IL6ST (gp130), signals through STAT1 and STAT3 to drive immune responses such as Th1 differentiation, cytotoxic T cell proliferation, and IFN-γ production. IL-27 shows context-dependent dual actions in hematological and solid tumors. It can suppress tumor growth, but may also promote progression by inhibiting anti-tumor immunity or activating pro-tumor pathways. This update summarizes protumor and antitumor functions across cancer types.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-il-27-challenges-and-potential-in-cancer-immunotherapy/367055/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-il-27-challenges-and-potential-in-cancer-immunotherapy/367055.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is IL-27, and how does it signal to mediate immune effects?","Question",{"text":112,"@type":113},"IL-27 is a two-chain cytokine composed of IL-27p28 and EBI3. It signals through a heterodimer receptor containing IL27Rα (WSX1) and IL6ST (gp130), activating STAT1 and STAT3 pathways.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is IL-27 described as having both anti-tumor and pro-tumor roles?",{"text":117,"@type":113},"IL-27 exhibits context-dependent dual functions depending on biological setting, including the tumor microenvironment. It can enhance cytotoxic T lymphocyte and Th1 responses while also being able to promote tumor progression in some models.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the article aim to provide as an update?",{"text":121,"@type":113},"The study summarizes the protumor and antitumor biological functions of IL-27 across different hematological malignancies and solid tumors, highlighting its complexity as a cytokine target in cancer immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367055,1790863179,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Clinical and Experimental Medicine (2025) 25:34 [https://doi.org/10.1007/s10238-025-01562-w](https://doi.org/10.1007/s10238-025-01562-w)  \nHarnessing IL‑27: challenges and potential in cancer immunotherapy  \nAli Heidarnejad Maleki1 · Mansour Rajabivahid2 · Elnaz Khosh1 · Zeinab Khanali1 · SafaTahmasebi3 · Mahmood Dehghani Ghorbi4  \nReceived: 5 December 2024 / Accepted: 7 January 2025 / Published online: 11 January 2025 © The Author(s) 2025  \nAbstract  \nIL-27 is structurally an immune-enhancing and pleiotropic two-chain cytokine associated with IL-12 and IL-6 families. IL-27 contains two subunits, namely IL-27p28 and EBI3 . A heterodimer receptor of IL-27, composed of IL27Rα (WSX1)  \nand IL6ST (gp130) chains, mediates the IL-27 function following the activation of STAT1 and STAT3 signaling pathways. Specifically, IL-27 is identified as augmenting cytokine of immune responses, including Th1 cell differentiation, TCd4 + cell proliferation, and IFN-γ production with the help of IL-12. According to several published studies, due to the pro-inflammatory or anti-inflammatory functions of cytokine related to the biological context in various disorders and diseases, IL-27 has been considered a complex regulator of the immune system. Surprisingly, the dual role of IL-27, the same as the double-edged sword, has also been evidenced in clinical models of various hematological or solid tumors. Predominantly, Il-27 applies anti-tumor functions by inducing the responses of a cytotoxic T lymphocyte (CTL) and Th1 and suppressing the growth, proliferation, angiogenesis, invasiveness, metastasis, and survival of tumor cells. On the other hand, IL-27 may also play aprotumor role in cancers and induce tumor progression. The current update study aimed to summarize the protumor antitumor and biological functions of IL-27 in different hematological malignancies and solid tumors.  \nKeywords Immunotherapy · Interleukin-27 · Cancer · Hematological malignancy · Solid tumor  \nIntroduction  \nInterleukin-27 (IL-27) is a new member of the IL-12 family, first introduced as a heterodimeric cytokine in 2002. IL-27 consists of two subunits, IL-27p28 and Epstein-Barr  \nAli Heidarnejad Maleki and Mansour Rajabivahid have contributed equally to this article.  \n* Safa Tahmasebi [Safa.tahmasebi@sbmu.ac.ir](Safa.tahmasebi@sbmu.ac.ir)  \n* Mahmood Dehghani Ghorbi [dr.mahmooddehghani@gmail.com](dr.mahmooddehghani@gmail.com)  \n1 School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran  \n2 Department of Internal Medicine, Valiasr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran  \n3 Student Research Committee, Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \n4 Department of Hematology-Oncology, Imam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  \nvirus-induced gene 3 (EBI-3), which are expressed on activated antigen-presenting cells (APCs) [1, 2] . WSX-1 serves as an IL-27 receptor, expressed on various cells, and mediates the biological responses of IL-27 in different immune cells, such as T cells, B cells, and natural killer (NK) cells [1] .  \nIn recent decades, cancer treatment has made considerable progress, including immunotherapy-based methods revolutionizing the treatment of various cancers [3–5] . Immunotherapeutic strategies act via modulating the immune system activities, which include Adoptive cell therapy (ACT) [6], chimeric antigen receptor (CAR)-T cell therapy [4], monoclonal antibodies (mAbs) [7], vaccines [8], targeted therapy [9], immune checkpoint inhibitors [10], and cytokine based therapies [11] . Among immunotherapy approaches, CART cell therapy indicated considerable successes in autoimmune disease, hematological, solid cancers, asthma, and allergic disorders [12–15] . As a targeted therapy approach, Cytokine therapy is a potential method of immunotherapy in treating various diseases such as cancer, autoimmunity, infection","cbCaiuL87Mw8UcHD","https://ap.wps.com/l/cbCaiuL87Mw8UcHD","pdf",1390540,24,"English","# Abstract\n# Introduction\n## IL-27 structure and signaling\n## Rationale for cytokine-based immunotherapy in cancer\n## Clinical relevance and current research directions","[{\"question\":\"What is IL-27, and how does it signal to mediate immune effects?\",\"answer\":\"IL-27 is a two-chain cytokine composed of IL-27p28 and EBI3. It signals through a heterodimer receptor containing IL27Rα (WSX1) and IL6ST (gp130), activating STAT1 and STAT3 pathways.\"},{\"question\":\"Why is IL-27 described as having both anti-tumor and pro-tumor roles?\",\"answer\":\"IL-27 exhibits context-dependent dual functions depending on biological setting, including the tumor microenvironment. It can enhance cytotoxic T lymphocyte and Th1 responses while also being able to promote tumor progression in some models.\"},{\"question\":\"What does the article aim to provide as an update?\",\"answer\":\"The study summarizes the protumor and antitumor biological functions of IL-27 across different hematological malignancies and solid tumors, highlighting its complexity as a cytokine target in cancer immunotherapy.\"}]","Harnessing IL-27: challenges and potential in cancer immunotherapy | PDF",1790169087,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b75e95146e58ebae0a6c8f27a5cefc8c.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3368cb4f61986c7750c4b1561f5537fa.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f45c4d0a5f56c910f85da6309de3159.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f184ca1c85b7f19d2f66a2f6ac719f7.webp",980,1301]